European Commission approves Sobi and Ionis' Tryngolza for severe hypertriglyceridaemia

The European Commission has approved Tryngolza for adults with severe hypertriglyceridaemia, following Phase III results showing substantial triglyceride reductions and fewer acute pancreatitis events.
On 17 November 2026, the European Commission approved Tryngolza (olezarsen), developed by Ionis Pharmaceuticals and commercialised by Sobi in its licensed territories, as an adjunct to diet and other lipid-lowering therapies for adults with severe hypertriglyceridaemia and fasting triglyceride concentrations of at least 880 mg/dL.
The Phase III CORE and CORE2 studies reported mean triglyceride reductions of up to 73% at six months and an 83% reduction in acute pancreatitis event rates compared with placebo; this represents a final European Commission marketing authorisation rather than a preliminary CHMP recommendation, with national access dependent on subsequent commercial and reimbursement arrangements.
Field | Content |
Companies | Sobi and Ionis Pharmaceuticals |
Medicine | Tryngolza (olezarsen) |
Regulatory Authority | European Commission |
Approval Date | 17 November 2026 |
Approval Type | EU marketing authorisation |
Therapeutic Area | Cardiometabolic medicine |
Indication | Severe hypertriglyceridaemia |
Eligible Patients | Adults with fasting triglycerides of at least 880 mg/dL |
Treatment Regimen | Adjunct to diet and other lipid-lowering therapies |
Drug Modality | RNA-targeted medicine |
Supporting Studies | Phase III CORE and CORE2 |
Triglyceride Reduction | Mean reductions of up to 73% at six months |
Pancreatitis Outcome | 83% reduction in acute pancreatitis event rates versus placebo |
Development Partner | Ionis Pharmaceuticals |
Commercialisation Partner | Sobi in licensed territories outside the US excluding Canada and China |
Regulatory Significance | Final European Commission approval; not merely a positive CHMP opinion |
Primary Source | https://www.sobi.com/en/press-releases/tryngolzatm-olezarsen-approved-eu-severe-hypertriglyceridaemia-shtg-2498693 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com


Comentarios